KR20230118612A - 헤테로다이머화를 위한 직교 돌연변이 - Google Patents

헤테로다이머화를 위한 직교 돌연변이 Download PDF

Info

Publication number
KR20230118612A
KR20230118612A KR1020237022864A KR20237022864A KR20230118612A KR 20230118612 A KR20230118612 A KR 20230118612A KR 1020237022864 A KR1020237022864 A KR 1020237022864A KR 20237022864 A KR20237022864 A KR 20237022864A KR 20230118612 A KR20230118612 A KR 20230118612A
Authority
KR
South Korea
Prior art keywords
domain
sequence
amino acid
domains
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022864A
Other languages
English (en)
Korean (ko)
Inventor
조나단 해리 데이비스
니콜라스 엠. 마쉘
Original Assignee
인벤라 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인벤라 인코포레이티드 filed Critical 인벤라 인코포레이티드
Publication of KR20230118612A publication Critical patent/KR20230118612A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
KR1020237022864A 2020-12-10 2021-12-10 헤테로다이머화를 위한 직교 돌연변이 Pending KR20230118612A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123915P 2020-12-10 2020-12-10
US63/123,915 2020-12-10
PCT/US2021/062951 WO2022125986A1 (en) 2020-12-10 2021-12-10 Orthogonal mutations for heterodimerization

Publications (1)

Publication Number Publication Date
KR20230118612A true KR20230118612A (ko) 2023-08-11

Family

ID=81974005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022864A Pending KR20230118612A (ko) 2020-12-10 2021-12-10 헤테로다이머화를 위한 직교 돌연변이

Country Status (10)

Country Link
US (2) US12312418B2 (https=)
EP (1) EP4259194A4 (https=)
JP (1) JP2024500354A (https=)
KR (1) KR20230118612A (https=)
CN (1) CN116867514A (https=)
AU (1) AU2021397322A1 (https=)
CA (1) CA3207821A1 (https=)
IL (1) IL303518A (https=)
MX (1) MX2023006899A (https=)
WO (1) WO2022125986A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JP6385357B2 (ja) * 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2016130516A1 (en) * 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US10696722B2 (en) * 2016-08-10 2020-06-30 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
JP7438942B2 (ja) * 2017-10-30 2024-02-27 エフ． ホフマン－ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
US20210163594A1 (en) * 2018-04-17 2021-06-03 Invenra Inc. Binding molecules
KR102870868B1 (ko) * 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
JP7812230B2 (ja) * 2019-04-25 2026-02-09 エフ． ホフマン－ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
AU2021224883A1 (en) * 2020-02-20 2022-09-29 Invenra Inc. Bispecific GD2 and B7H2 binding molecules and methods of use

Also Published As

Publication number Publication date
AU2021397322A9 (en) 2024-06-20
WO2022125986A1 (en) 2022-06-16
AU2021397322A1 (en) 2023-07-06
EP4259194A1 (en) 2023-10-18
JP2024500354A (ja) 2024-01-09
US20260078202A1 (en) 2026-03-19
US20220363782A1 (en) 2022-11-17
CN116867514A (zh) 2023-10-10
IL303518A (en) 2023-08-01
EP4259194A4 (en) 2025-03-19
US12312418B2 (en) 2025-05-27
MX2023006899A (es) 2023-09-04
CA3207821A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
CN107207592B (zh) 结构域交换的抗体
JP7138046B2 (ja) 二特異性抗体基幹
JP6104121B2 (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP6385357B2 (ja) 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
KR20230156079A (ko) Cd3과 cldn6에 결합하는 이종이량체 항체
US20260078202A1 (en) Orthogonal mutations for heterodimerization
JP7123063B2 (ja) 抗体ドメインの好ましい対形成
KR20200067197A (ko) 단일특이적 항체로부터 다중특이적 항체의 생성 방법
EP3728328A1 (en) Bispecific antigen binding construct
JP2025537782A (ja) 活性化可能なエフェクタードメインを有する組換え結合タンパク質
WO2025092987A1 (zh) 基于Fc区的异二聚体分子及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230705

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241209

Comment text: Request for Examination of Application